Alligator Bioscience announces financing of up to SEK 80 million extending cash runway to Q1 2025
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...
Alligator Bioscience to Present Positive Phase 2 Data on Mitazalimab in Pancreatic Cancer at ESMO GI 2024
Primary endpoint of OPTIMIZE-1 trial was met, with Objective Response Rate (ORR) of 40.4% in 57 evaluable patients Unprecedented Duration of ...
Alligator Bioscience’s Phase 2 mitazalimab Pancreatic Cancer Data Published in The Lancet Oncology
Publication in world-leading clinical oncology journal validates the quality and potential implications of Phase 2 OPTIMIZE-1 results The st ...
Alligator Bioscience to Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO Annual Meeting
OPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-n ...
Alligator Bioscience’s Announces Henlius Biotech has Received FDA IND Clearance for Phase 3 Initiation to Evaluate HLX22 (AC101) in 1st Line HER2+ Advanced Gastric Cancer
FDA IND follows promising Phase 2 results presented at 2024 ASCO GI revealing that the addition of HLX22 (AC101) to biosimilar trastuzumab a ...
Alligator Bioscience Announces Publication Highlighting Potential of Next-Generation CD40 Agonists in Peer-Reviewed Medical Journal “Expert Opinion on Biological Therapy”
Next-generation CD40 agonists have opportunity to address key biological and medical needs in immuno-oncology Bispecific CD40-targeting anti ...
Alligator Bioscience Announces Initiation of an Investigator-Initiated Initiation of Phase 1 Clinical Study of Intratumoral Mitazalimab in Locally Advanced Pancreatic Cancer
Study conducted by Moores Cancer Center at University of California San Diego to evaluate safety and efficacy of mitazalimab injected intrat ...
Alligator Bioscience and Orion Corporation announce exercise of development option under 2021 Immuno-oncology Research Collaboration and License Agreement
Orion selects lead antibodies from the second discovery program Collaboration aims to discover and develop new bispecific antibody cancer th ...
Last day of trading in paid subscribed units (Sw. BTU) in Alligator
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO, THE UNITED STATES OF AMERICA, AUSTRALIA, BELARUS, CANADA, ...